Site Editor

Sandy Srinivas, MD

Advertisement

Advertisement

News

SUO 2023: Toxicity Trends With Radioligand Therapy for Prostate Cancer

News

SUO 2023: Is Radioligand Therapy Safe for Patients With Prostate Cancer and Baseline Cytopenia?

News

Understanding Men’s Communication Preferences When Discussing Prostate Cancer Screening

Medical Literature

Researchers Examine Use of Chinese Herbal Medicines to Treat Prostate Cancer

News

SUO 2023: Is Radioligand Therapy Safe for Patients With Prostate Cancer and Baseline Cytopenia?

News

Understanding Men’s Communication Preferences When Discussing Prostate Cancer Screening

Medical Literature

Can MRI Improve Detection of Clinically Significant Prostate Cancer?

Sandy Srinivas, MD, on Treatment Alternatives for Metastatic Castration-Resistant Prostate Cancer During Radioligand Therapy Shortage

Scott T. Tagawa, MD, on Clinical Implications of Using an Anti-PSMA Antibody With Ketoconazole, Hydrocortisone, and Lutetium-177 in Treatment of Prostate Cancer

View More

Advertisement

JNCCN Spotlights

Darolutamide

Lutetium Lu-177 Vipivotide Tetraxetan

(UPDATE) Apalutamide in Prostate Cancer

(UPDATE) Degarelix (Injectable GnRH Antagonist)

(2nd UPDATE) Enzalutamide

(1st UPDATE) Enzalutamide

Docetaxel (Castration-Naive Metastatic Prostate Cancer)

Degarelix (Injectable GnRH Antagonist)

View More

More

News

PARP Inhibitors and Prostate Cancer: Perceptions of Surveyed Practicing Oncologists

ASTRO 2023: Strategy for Reducing Genomic Testing Inequities in Prostate Cancer

Out-of-Pocket Costs for Prostate Cancer Drugs in Medicare Part D Plans

Can Radiotherapy Prime Immune System in Oligometastatic Prostate Cancer?

Diagnostic and Treatment Disparities Among Hispanic Men With Metastatic Prostate Cancer

SNMMI Weighs in on Use of Radionuclide Therapy for Metastatic Prostate Cancer

SUO 2023: Is Radioligand Therapy Safe for Patients With Prostate Cancer and Baseline Cytopenia?

SUO 2023: Toxicity Trends With Radioligand Therapy for Prostate Cancer

View More

Advertisement

Published

Medical Literature

Novel Methylation-Based Biomarkers May Predict Prostate Cancer Mortality

Are Prostate Tumor Germline Mutations Linked to Genetic Ancestry?

20-Year Experience With Whole Gland Cryoablation in Patients With Prostate Cancer

Can a Novel Genetic Scoring Method Predict the Risk for Aggressive Prostate Cancer?

View More

Ongoing

CE Activities

Genitourinary Cancers: Assessing the Roles of Immune-Based and Targeted Therapies in a Changing Treatment Landscape

Talk to Someone: Explore Talking to Patients About Prostate Cancer Treatment

Management of Metastatic Prostate Cancer

Prostate Cancer in Black Individuals: How Can We Do Better

View More

Available

Clinical Trials

Phase II Study of Pencil Beam Scanning Proton Stereotactic Body Radiation Therapy for Prostate Cancer

Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial

Randomized Phase II Trial of Salvage Radiotherapy for Prostate Cancer In 4 Weeks v. 2 Weeks

Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk with Radiation

View More

Resources

For Your Patients

Prostate Health Education Network

Urology Care Foundation

Cancer Support Community

Prostate Cancer Foundation

View More

Sections

360 Hub

NCCN Resources

Copyright^© 2023 National Comprehensive Cancer Network, All Rights Reserved

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.